A clinical- and cost-effectiveness comparison of venlafaxine and selective serotonin reuptake inhibitors (SSRIs) in the management of patients with major depressive disorder from the perspective of an Austrian sickness fund
Authors:
- P HowardPHP Howard
- C KnightCKC Knight
- 1 January 2004
- journal article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 7 (1-4) , 93-106
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Cost Effectiveness of Representatives of Three Classes of Antidepressants Used in Major Depression in the UKPharmacoEconomics, 2004
- Treatment strategies in achieving remission in major depressive disorderActa Psychiatrica Scandinavica, 2002
- Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitorsThe British Journal of Psychiatry, 2001
- A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAsValue in Health, 2001
- Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.PharmacoEconomics, 2000
- A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depressionJournal of Affective Disorders, 1999
- Once-Daily Venlafaxine Extended Release (XR) Compared With Fluoxetine in Outpatients With Depression and AnxietyThe Journal of Clinical Psychiatry, 1999
- A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatientsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1996
- A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disordersClinical Therapeutics, 1995
- A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholiaInternational Clinical Psychopharmacology, 1994